scholarly journals Human(ized) monoclonal antibodies in atopic patients – state of the art

2020 ◽  
Vol 45 (2) ◽  
pp. 195-201
Author(s):  
Arzu Didem Yalcin ◽  
Kevser Onbasi ◽  
Rusen Uzun ◽  
Felix Herth ◽  
Philipp Albert Schnabel
Keyword(s):  
Monoclonal Antibodies ◽  
State Of The Art

scholarly journals Designer monoclonal antibodies as drugs: the state of the art

2008 ◽  
Vol 4 (3) ◽  
pp. 305-307 ◽  
Author(s):  
Shyam Mohapatra ◽  
Homero San Juan
Keyword(s):  
Monoclonal Antibodies ◽  
State Of The Art ◽  
The State

scholarly journals Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives

2010 ◽  
Vol 2010 ◽  
pp. 1-14 ◽  
Author(s):  
Giulia Motta ◽  
Michele Cea ◽  
Eva Moran ◽  
Federico Carbone ◽  
Valeria Augusti ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Cancer Treatment ◽  
B Cell ◽  
Clinical Studies ◽  
State Of The Art ◽  
Optimal Duration ◽  
Cd20 Antibody ◽  
Anti Cd20 ◽  
Hodgkin's Lymphomas ◽  
Administration Schedules

Monoclonal antibodies have been the most successful therapeutics ever brought to cancer treatment by immune technologies. The use of monoclonal antibodies in B-cell Non-Hodgkin's lymphomas (NHL) represents the greatest example of these advances, as the introduction of the anti-CD20 antibody rituximab has had a dramatic impact on how we treat this group of diseases today. Despite this success, several questions about how to optimize the use of monoclonal antibodies in NHL remain open. The best administration schedules, as well as the optimal duration of rituximab treatment, have yet to be determined. A deeper knowledge of the mechanisms underlying resistance to rituximab is also necessary in order to improve the activity of this and of similar therapeutics. Finally, new antibodies and biological agents are entering the scene and their advantages over rituximab will have to be assessed. We will discuss these issues and present an overview of the most significant clinical studies with monoclonal antibodies for NHL treatment carried out to date.

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

2011 ◽  
Vol 11 (11) ◽  
pp. 1433-1445 ◽  
Author(s):  
Gaetana Di Fede ◽  
Giuseppe Bronte ◽  
Sergio Rizzo ◽  
Christian Rolfo Cervetto ◽  
Gianfranco Cocorullo ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
State Of The Art ◽  
Antibody Fragments ◽  
Future Perspectives

scholarly journals State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer

2021 ◽  
Vol Volume 15 ◽  
pp. 451-462
Author(s):  
Debora Basile ◽  
Francesca Simionato ◽  
Alessandro Cappetta ◽  
Silvio Ken Garattini ◽  
Giandomenico Roviello ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Monoclonal Antibodies ◽  
State Of The Art

State-of-the-art treatment of chronic lymphocytic leukemia

Hematology ◽  
2009 ◽  
Vol 2009 (1) ◽  
pp. 440-449 ◽  
Author(s):  
Michael Hallek
Keyword(s):  
Monoclonal Antibodies ◽  
Chronic Lymphocytic Leukemia ◽  
Progenitor Cell ◽  
Prognostic Markers ◽  
State Of The Art ◽  
Lymphocytic Leukemia ◽  
Regulatory Agencies ◽  
Rapid Progress ◽  
Therapeutic Decisions ◽  
Reduced Intensity

AbstractThe last decade has produced rapid progress in the management of chronic lymphocytic leukemia (CLL). Fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab, have been approved by the European and/or American regulatory agencies. Several, novel monoclonal antibodies targeting CD20, CD23 or CD40, as well as drugs designed to interfere with proteins regulating the cell cycle, apoptotic machinery, or leukemic microenvironment (eg, flavopiridol, oblimersen, or lenalidomide), are currently being tested in clinical trials. Furthermore, the increased experience with reduced-intensity allogeneic progenitor cell transplantation allows offering this option to physically fit patients. In addition, new prognostic markers that may influence therapeutic decisions have been identified. This review attempts to summarize the current use of these different modalities in CLL therapy.

scholarly journals Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1420 ◽  
Author(s):  
Malgorzata Bobrowicz ◽  
Radoslaw Zagozdzon ◽  
Joanna Domagala ◽  
Roberta Vasconcelos-Berg ◽  
Emmanuella Guenova ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
State Of The Art ◽  
Molecular Targets ◽  
Immune Checkpoints ◽  
Future Perspectives ◽  
Solid Malignancies ◽  
Specific Proteins ◽  
Modern Treatment ◽  
Anti Cd20 ◽  
Established Role

Monoclonal antibodies (mAbs) targeting specific proteins are currently the most popular form of immunotherapy used in the treatment of cancer and other non-malignant diseases. Since the first approval of anti-CD20 mAb rituximab in 1997 for the treatment of B-cell malignancies, the market is continuously booming and the clinically used mAbs have undergone a remarkable evolution. Novel molecular targets are constantly emerging and the development of genetic engineering have facilitated the introduction of modified mAbs with improved safety and increased capabilities to activate the effector mechanisms of the immune system. Next to their remarkable success in hematooncology, mAbs have also an already established role in the treatment of solid malignancies. The recent development of mAbs targeting the immune checkpoints has opened new avenues for the use of this form of immunotherapy, also in the immune-rich milieu of the skin. In this review we aim at presenting a comprehensive view of mAbs’ application in the modern treatment of skin cancer. We present the characteristics and efficacy of mAbs currently used in dermatooncology and summarize the recent clinical trials in the field. We discuss the side effects and strategies for their managing.

scholarly journals The Relevance of Monoclonal Antibodies in the Treatment of COVID-19

Vaccines ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 557
Author(s):  
Anabel Torrente-López ◽  
Jesús Hermosilla ◽  
Natalia Navas ◽  
Luis Cuadros-Rodríguez ◽  
José Cabeza ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Immune System ◽  
State Of The Art ◽  
Virus Protein ◽  
Immune Disorders ◽  
The Subject ◽  
New Treatments ◽  
Therapeutic Monoclonal Antibodies ◽  
Made In

Major efforts have been made in the search for effective treatments since the outbreak of the COVID-19 infection in December 2019. Extensive research has been conducted on drugs that are already available and new treatments are also under development. Within this context, therapeutic monoclonal antibodies (mAbs) have been the subject of widespread investigation focusing on two target-based groups, i.e., non-SARS-CoV-2 specific mAbs, that target immune system responses, and SARS-CoV-2 specific mAbs, designed to neutralize the virus protein structure. Here we review the latest literature about the use of mAbs in order to describe the state of the art of the clinical trials and the benefits of using these biotherapeutics in the treatment of COVID-19. The clinical trials considered in the present review include both observational and randomized studies. We begin by presenting the studies conducted using non-SARS-CoV-2 specific mAbs for treating different immune disorders that were already on the market. Within this group of mAbs, we focus particularly on anti-IL-6/IL-6R. This is followed by a discussion of the studies on SARS-CoV-2 specific mAbs. Our findings indicate that SARS-CoV-2 specific mAbs are significantly more effective than non-specific ones.

Sign in / Sign up

Export Citation Format

Share Document